title: Analysis of 120 pediatric patients with nonmalignant disorders transplanted using unrelated plasma-depleted or -reduced cord blood.
abstract: BACKGROUND
  Unrelated cord blood (CB) is an important stem cell source for unrelated hematopoietic cell transplantation (HCT) of patients with nonmalignant disorders. Processing methods to prepare red blood cell-reduced CB units incur significant nucleated cell loss. In contrast, plasma depletion or reduction (PDR) processing of CB units entails the removal of only a portion of the plasma with minimal nucleated cell loss. However, there are relatively limited data regarding outcomes of CB transplants using units processed by PDR.
  
  
  METHODS
  A Center for International Blood and Marrow Transplant Research (CIBMTR)-audited analysis was performed on 120 pediatric patients with nonmalignant disorders transplanted between November 2001 and January 2008 at 29 US and 17 international centers using PDR CB units from two CB banks.
  
  
  RESULTS
  Transplant characteristics were as follows: median age, 3.5 years (range, 0.1-14 years); median patient weight, 15 kg (range, 4-61 kg); 58% male; HLA matches (intermediate-resolution HLA-A and HLA-B and high-resolution HLA-DRB1) of the units used in these patients six of six in 26, five of six in 48, four of six in 47, and three of six or two of six in 6; median prefreeze total nucleated cell dose, 10.5×10(7)/kg; median prefreeze CD34+ dose, 3.7×10(5)/kg; and nonmyeloablative regimen in 24%. The median times to myeloid and platelet engraftment were 21 and 49 days, respectively. The cumulative incidence of reported Grade II to IV acute graft-versus-host disease (aGVHD) was 38±5%, and 19±4% had Grade III to IV aGVHD. The Kaplan-Meier estimates of 3-year transplant-related mortality, overall survival, and disease-free survival were 20±4, 79±4, and 70±6%, respectively.
  
  
  CONCLUSIONS
  These data demonstrate the effectiveness of PDR CB units for HCT.
authors.affiliation: StemCyte International Cord Blood Center, Covina, California 91722, USA.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Petz
authors.forename: Tang-Her
authors.initials: TH
authors.lastname: Jaing
authors.forename: Joseph
authors.initials: J
authors.lastname: Rosenthal
authors.forename: Chatchada
authors.initials: C
authors.lastname: Karanes
authors.forename: Auayporn
authors.initials: A
authors.lastname: Nademanee
authors.forename: Lee Lee
authors.initials: LL
authors.lastname: Chan
authors.forename: Michael L
authors.initials: ML
authors.lastname: Graham
authors.forename: Hai Peng
authors.initials: HP
authors.lastname: Lin
authors.forename: Patrick
authors.initials: P
authors.lastname: Tan
authors.forename: B C
authors.initials: BC
authors.lastname: Wang
authors.forename: Chen
authors.initials: C
authors.lastname: Fu
authors.forename: Michelle
authors.initials: M
authors.lastname: Chow
authors.forename: Stephen
authors.initials: S
authors.lastname: Forman
authors.forename: Robert
authors.initials: R
authors.lastname: Chow
mesh_terms: D000293:Adolescent; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D016238:Cytapheresis / Q000379:methods; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology; D006402:Hematologic Diseases / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010956:Plasmapheresis / Q000379:methods; D061349:Unrelated Donors / Q000706:statistics & numerical data